RxDoctor Payments Data

Miranda Ku, MD

Gastroenterology · Highlands Ranch, CONPI 1770513426

Payments from drug & device makers

$1,383in general payments, 2019–2025

Across 72 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$431
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$285
  • Phathom Pharmaceuticals, Inc.$123
  • Braintree Laboratories, Inc.$94
  • Olympus America Inc.$84
  • ERBE USA Inc$64
  • plus $303 from 10 others

What the payments were for

  • Food & beverage$1,35498%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,383 in reported general payments places this provider in the 40th percentile of 304 gastroenterology providers in Colorado.

See all gastroenterology providers in Colorado

Medicare billing

Part B allowed, 2024
$72,130
Medicare patients
269
Services billed
436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin15$35,111
LinzessLinaclotide32$26,123
TrulancePlecanatide13$7,301
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates80$5,396
Omeprazole132$2,211
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl107$1,671
CholestyramineCholestyramine (With Sugar)24$1,645
Sodium Chloride0.9 % Sodium Chloride21$952
Famotidine73$705
Dicyclomine Hcl18$530
Baclofen13$484
Neomycin Sulfate11$365
Ondansetron HclOndansetron Hcl/Pf16$250
Metronidazole11$86
Lactulose14$39

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$285$42,41228 claims
AbbVieLinzess$431$26,12332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 304 gastroenterology providers in Colorado.

Other gastroenterology in Highlands Ranch

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →